Search

Your search keyword '"Dwyer, Jamie P."' showing total 346 results
Start Over Author "Dwyer, Jamie P."
346 results on '"Dwyer, Jamie P."'

51. Sotagliflozin in patients with diabetes and chronic kidney disease

Author

Bhatt, Deepak L., Szarek, Michael, Pitt, Bertram, Cannon, Christopher P., Leiter, Lawrence A., McGuire, Darren K., Lewis, Julia B., Riddle, Matthew C., Inzucchi, Silvio E., Kosiborod, Mikhail N., Cherney, David Z.I., Dwyer, Jamie P., Scirica, Benjamin M., Bailey, Clifford J., Díaz, Rafael, Ray, Kausik K., Udell, Jacob A., Lopes, Renato D., Lapuerta, Pablo, Gabriel Steg, P., Bhatt, Deepak L., Szarek, Michael, Pitt, Bertram, Cannon, Christopher P., Leiter, Lawrence A., McGuire, Darren K., Lewis, Julia B., Riddle, Matthew C., Inzucchi, Silvio E., Kosiborod, Mikhail N., Cherney, David Z.I., Dwyer, Jamie P., Scirica, Benjamin M., Bailey, Clifford J., Díaz, Rafael, Ray, Kausik K., Udell, Jacob A., Lopes, Renato D., Lapuerta, Pablo, and Gabriel Steg, P.

Abstract

BACKGROUND: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. METHODS: We conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, ≥7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m 2 of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding. RESULTS: Of 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0.35). For the original coprimary end point of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, the hazard ratio was 0.84 (95% CI, 0.72 to 0.99); for the original coprimary end point of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, the hazard ratio was 0.77 (95% CI, 0.66 to 0.91). Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo. CONCLUSIONS: In patie

Published
2021

52. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death:an individual participant-level data meta-analysis

Author

Rahimi, Kazem, Bidel, Zeinab, Nazarzadeh, Milad, Copland, Emma, Canoy, Dexter, Wamil, Malgorzata, Majert, Jeannette, McManus, Richard, Adler, Amanda, Agodoa, Larry, Algra, Ale, Asselbergs, Folkert W., Beckett, Nigel S., Berge, Eivind, Black, Henry, Boersma, Eric, Brouwers, Frank P.J., Brown, Morris, Brugts, Jasper J., Bulpitt, Christopher J., Byington, Robert P., Cushman, William C., Cutler, Jeffrey, Devereaux, Richard B., Dwyer, Jamie P., Estacio, Ray, Fagard, Robert, Fox, Kim, Fukui, Tsuguya, Gupta, Ajay K., Holman, Rury R., Imai, Yutaka, Ishii, Masao, Julius, Stevo, Kanno, Yoshihiko, Kjeldsen, Sverre E., Kostis, John, Kuramoto, Kizuku, Lanke, Jan, Lewis, Edmund, Lewis, Julia B., Lievre, Michel, Lindholm, Lars H., Lueders, Stephan, MacMahon, Stephen, Mancia, Giuseppe, Matsuzaki, Masunori, Mehlum, Maria H., Nissen, Steven, Ogawa, Hiroshi, Rahimi, Kazem, Bidel, Zeinab, Nazarzadeh, Milad, Copland, Emma, Canoy, Dexter, Wamil, Malgorzata, Majert, Jeannette, McManus, Richard, Adler, Amanda, Agodoa, Larry, Algra, Ale, Asselbergs, Folkert W., Beckett, Nigel S., Berge, Eivind, Black, Henry, Boersma, Eric, Brouwers, Frank P.J., Brown, Morris, Brugts, Jasper J., Bulpitt, Christopher J., Byington, Robert P., Cushman, William C., Cutler, Jeffrey, Devereaux, Richard B., Dwyer, Jamie P., Estacio, Ray, Fagard, Robert, Fox, Kim, Fukui, Tsuguya, Gupta, Ajay K., Holman, Rury R., Imai, Yutaka, Ishii, Masao, Julius, Stevo, Kanno, Yoshihiko, Kjeldsen, Sverre E., Kostis, John, Kuramoto, Kizuku, Lanke, Jan, Lewis, Edmund, Lewis, Julia B., Lievre, Michel, Lindholm, Lars H., Lueders, Stephan, MacMahon, Stephen, Mancia, Giuseppe, Matsuzaki, Masunori, Mehlum, Maria H., Nissen, Steven, and Ogawa, Hiroshi

Abstract

Background: The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline. Methods: We did a meta-analysis using individual participant-level data from randomised controlled trials of pharmacological blood-pressure-lowering versus placebo or other classes of blood-pressure-lowering medications, or between more versus less intensive treatment strategies, which had at least 1000 persons-years of follow-up in each treatment group. Participants with previous history of heart failure were excluded. Data were obtained from the Blood Pressure Lowering Treatment Triallists' Collaboration. We pooled the data and categorised participants into baseline age groups (<55 years, 55–64 years, 65–74 years, 75–84 years, and ≥85 years) and blood pressure categories (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg systolic blood pressure and from <70 mm Hg to ≥110 mm Hg diastolic). We used a fixed effects one-stage approach and applied Cox proportional hazard models, stratified by trial, to analyse the data. The primary outcome was defined as either a composite of fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring hospital admission. Findings: We included data from 358 707 participants from 51 randomised clinical trials. The age of participants at randomisation ranged from 21 years to 105 years (median 65 years [IQR 59–75]), with 42 960 (12·0%) participants younger than 55 years, 128 437 (35·8%) aged 55–64 years, 128 506 (35·8%) 65–74 years, 54 016 (15·1%) 75–84 years, and 4788 (1·3%) 85 years and older. The hazard ratios for the risk of major cardiovascular events per 5 mm

Published
2021

53. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial : baseline characteristics

Author

Wheeler, David C., Stefansson, Bergur, V, Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z., I, Chertow, Glenn M., Douthat, Walter, Dwyer, Jamie P., Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Gorriz, Jose Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin-Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B., McMurray, John J., V, Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D., Umanath, Kausik, Van Bui, Pham, Wittmann, Istvan, Lindberg, Magnus, Sjostrom, C. David, Langkilde, Anna Maria, Heerspink, Hiddo J. L., Wheeler, David C., Stefansson, Bergur, V, Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z., I, Chertow, Glenn M., Douthat, Walter, Dwyer, Jamie P., Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Gorriz, Jose Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin-Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B., McMurray, John J., V, Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D., Umanath, Kausik, Van Bui, Pham, Wittmann, Istvan, Lindberg, Magnus, Sjostrom, C. David, Langkilde, Anna Maria, and Heerspink, Hiddo J. L.

Abstract

Background. The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods. In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) <= 200mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75mL/min/1.73m(2) were randomized to dapagliflozin 10mg once daily or placebo. Mean eGFR was 43.1mL/min/1.73m(2) and median UACR was 949 mg/g (108mg/mmol). Results. Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensinconverting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1mL/min/1.73m(2) lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). Conclusions. Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy

Published
2020
Full Text
View/download PDF

54. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial:baseline characteristics

Author

Wheeler, David C., Stefansson, Bergur V., Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z.I., Chertow, Glenn M., Douthat, Walter, Dwyer, Jamie P., Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Górriz, José Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B., McMurray, John J.V., Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D., Umanath, Kausik, Van Bui, Pham, Wittmann, István, Lindberg, Magnus, Sjöström, C. David, Langkilde, Anna Maria, Heerspink, Hiddo J.L., Wheeler, David C., Stefansson, Bergur V., Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z.I., Chertow, Glenn M., Douthat, Walter, Dwyer, Jamie P., Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Górriz, José Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B., McMurray, John J.V., Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D., Umanath, Kausik, Van Bui, Pham, Wittmann, István, Lindberg, Magnus, Sjöström, C. David, Langkilde, Anna Maria, and Heerspink, Hiddo J.L.

Abstract

BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. METHODS: In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Mean eGFR was 43.1 mL/min/1.73 m2 and median UACR was 949 mg/g (108 mg/mmol). RESULTS: Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1 mL/min/1.73 m2 lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). CONCLUSIONS: Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking thera

Published
2020

55. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Author

Bhatt, Deepak L., primary, Szarek, Michael, additional, Pitt, Bertram, additional, Cannon, Christopher P., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Lewis, Julia B., additional, Riddle, Matthew C., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Cherney, David Z.I., additional, Dwyer, Jamie P., additional, Scirica, Benjamin M., additional, Bailey, Clifford J., additional, Díaz, Rafael, additional, Ray, Kausik K., additional, Udell, Jacob A., additional, Lopes, Renato D., additional, Lapuerta, Pablo, additional, and Steg, P. Gabriel, additional

Published
2021
Full Text
View/download PDF

56. Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice

Author

Drawz, Paul E., primary, Agarwal, Anil, additional, Dwyer, Jamie P., additional, Horwitz, Edward, additional, Lash, James, additional, Lenoir, Kristin, additional, McWilliams, Andrew, additional, Oparil, Suzanne, additional, Rahbari-Oskoui, Frederic, additional, Rahman, Mahboob, additional, Parkulo, Mark A., additional, Pemu, Priscilla, additional, Raj, Dominic S., additional, Rocco, Michael, additional, Soman, Sandeep, additional, Thomas, George, additional, Tuot, Delphine S., additional, Whelton, Paul K., additional, and Pajewski, Nicholas M., additional

Published
2020
Full Text
View/download PDF

61. Contributors

Author

Adler, Sharon, primary, Adrogué, Horacio J., additional, Aiyagari, Venkatesh, additional, Alpern, Robert J., additional, Alpers, Charles E., additional, Appel, Gerald B., additional, Arogundade, Fatiu A., additional, Ash, Stephen R., additional, Asif, Arif, additional, Aucouturier, Pierre, additional, August, Phyllis, additional, Bakris, George L., additional, Barlow, Adam D., additional, Barsoum, Rashad S., additional, Baylis, Chris, additional, Bello, Aminu, additional, Berl, Tomas, additional, Bhat, Suresh, additional, Bircher, Gemma, additional, Bonventre, Joseph V., additional, Bouchard, Josée, additional, Brook, Nicholas R., additional, Brown, Christopher, additional, Brown, Mark A., additional, Burdmann, Emmanuel A., additional, Bushinsky, David A., additional, Cattran, Daniel C., additional, Cervelli, Matthew J., additional, Chadban, Steven J., additional, Charlton, Karen E., additional, Chen, Yipu, additional, Cheng, Ignatius K.P., additional, Connolly, John O., additional, Couser, William G., additional, Cravedi, Paolo, additional, D’Agati, Vivette D., additional, Danovitch, Gabriel M., additional, Davies, Simon J., additional, Davison, John M., additional, Derman, Wayne, additional, DiBona, Gerald F., additional, Drüeke, Tilman B., additional, Dwyer, Jamie P., additional, Eckardt, Kai-Uwe, additional, Eckel, Jason, additional, Eitner, Frank, additional, Kossi, Mohsen El, additional, Elger, Marlies, additional, Elhassan, Elwaleed A., additional, Evenepoel, Pieter, additional, Fabian, June, additional, Falk, Ronald J., additional, Feehally, John, additional, Fischer, Evelyne A., additional, Fisher, Jonathan S., additional, Floege, Jürgen, additional, Fogazzi, Giovanni B., additional, Foreman, John W., additional, Fujita, Toshiro, additional, Gennari, F. John, additional, Gkougkousis, Evangelos G., additional, Glassock, Richard J., additional, Gorelick, Philip B., additional, Greco, Barbara A., additional, Gross, Peter, additional, Guay-Woodford, Lisa M., additional, Haddad, Nabil, additional, Harris, Kevin P.G., additional, Harris, Peter C., additional, Hebert, Lee A., additional, Heduschka, Peter, additional, Herzog, Charles A., additional, Hooton, Thomas, additional, Hörl, Walter H., additional, Hoyer, Peter F., additional, Hughes, Jeremy, additional, Hugo, Christian, additional, Imai, Enyu, additional, Irish, Ashley B., additional, Jaber, Bertrand L., additional, Jain, Sunjay, additional, Jayne, David, additional, Jefferson, J. Ashley, additional, Jennette, J. Charles, additional, Jha, Vivekanand, additional, Johnson, Richard J., additional, Kanagasundaram, Nigel S., additional, Kanellis, John, additional, Karumanchi, S. Ananth, additional, Kashtan, Clifford E., additional, Kauffman, Carol A., additional, Kawar, Bisher, additional, Kestenbaum, Bryan, additional, Ketteler, Markus, additional, Kopp, Jeffrey, additional, Kotanko, Peter, additional, Kriz, Wilhelm, additional, Kuhlmann, Martin K., additional, Kuypers, Dirk R., additional, Lakey, Jonathan R.T., additional, Lambert, Estelle V., additional, Lawton, William, additional, Levey, Andrew S., additional, Levin, Nathan W., additional, Levy, Jeremy, additional, Lewington, Andrew, additional, Lewis, Julia B., additional, Li, Felix F.K., additional, Linas, Stuart L., additional, Luft, Friedrich C., additional, Maaten, Jan C. ter, additional, Macdougall, Iain C., additional, Macedo, Etienne, additional, Madias, Nicolaos E., additional, Magee, Colm C., additional, Marsh, Christopher L., additional, Marshall, Mark R., additional, Martin, Kevin J., additional, Mason, Philip D., additional, Mathews, Ranjiv, additional, Mattoo, Tej K., additional, Mehta, Ravindra L., additional, Meier-Kriesche, Herwig-Ulf, additional, Mellon, J. Kilian, additional, Mirbolooki, M. Reza, additional, Monk, Rebeca D., additional, Moulin, Bruno, additional, Mulley, William R., additional, Nahas, Meguid El, additional, Naicker, Saraladevi, additional, Nangaku, Masaomi, additional, Neild, Guy H., additional, Nicholls, M. Gary, additional, Nicholson, Michael L., additional, O’Connell, Philip J., additional, O’Neill, W. Charles, additional, Palmer, Biff F., additional, Parikh, Chirag, additional, Pham, Phuong-Chi T., additional, Pham, Phuong-Thu T., additional, Pham, Son V., additional, Phelps, Richard G., additional, Pichler, Raimund, additional, Podymow, Tiina, additional, Pommer, Wolfgang, additional, Pusey, Charles D., additional, Rabb, Hamid, additional, Rayner, Brian, additional, Rayner, Hugh C., additional, Remuzzi, Giuseppe, additional, Richards, A. Mark, additional, Rippe, Bengt, additional, Ritz, Eberhard, additional, Robertson, R. Paul, additional, Rodriguez-Iturbe, Bernardo, additional, Ronco, Claudio, additional, Ronco, Pierre M., additional, Ross, Edward A., additional, Rossert, Jerome A., additional, Ruggenenti, Piero, additional, Ruland, Sean, additional, Russ, Graeme R., additional, Samuels, Martin A., additional, Sarafidis, Pantelis A., additional, Schena, F. Paolo, additional, Schold, Jesse D., additional, Schrier, Robert W., additional, Seabra, Victor F., additional, Segal, Mark S., additional, Seifter, Julian Lawrence, additional, Shastri, Shani, additional, Shirley, David G., additional, Sitprija, Visith, additional, Srinivas, Titte R., additional, Stenvinkel, Peter, additional, Stevens, Lesley A., additional, Textor, Stephen C., additional, Thurman, Joshua M., additional, Tong, Li-Li, additional, Topham, Peter S., additional, Tordoir, Jan H.M., additional, Torres, Vicente E., additional, Trence, Dace, additional, Turner, A. Neil, additional, Unwin, Robert J., additional, Vacher-Coponat, Henri, additional, Visweswaran, R. Kasi, additional, Wasse, Haimanot, additional, Wavamunno, Moses D., additional, Weiner, I. David, additional, Wheeler, David C., additional, Williams, Bryan, additional, Williams, John D., additional, Wingo, Charles S., additional, Winn, Michelle, additional, Wiseman, Alexander C., additional, Wolf, Gunter, additional, Womer, Karl, additional, Woodrow, Graham, additional, Wymer, David C., additional, Yang, Li, additional, and Yu, Xueqing, additional

Published
2010
Full Text
View/download PDF

63. Lead Authors and Contributors

Author

Benjamin, Ivor J., primary, Tariq, Sara G., additional, Beland, Susan S., additional, Benjamin, Ivor J., additional, Bull, David, additional, Hamdan, Mohamed H., additional, Li, Dean Y., additional, Litwin, Sheldon E., additional, Michaels, Andrew D., additional, Morshedzadeh, Jack H., additional, Stehlik, Josef, additional, Whitehead, Kevin J., additional, Victor, Ronald G., additional, Vongpatanasin, Wanpen, additional, Rounds, Sharon I., additional, Aliotta, Jason M., additional, Casserly, Brian, additional, Jankowich, Matthew D., additional, McCool, F. Dennis, additional, Eagle, Kim A., additional, Lau, Wei C., additional, Harris, Raymond C., additional, Andreoli, Thomas E., additional, Basford, Amanda W., additional, Cavanaugh, Kerri L., additional, Dwyer, Jamie P., additional, Golper, Thomas A., additional, Krause, Michelle W., additional, Ikizler, T. Alp, additional, Lewis, Julia B., additional, Luther, James M., additional, Pirkle, James L., additional, Portilla, Didier, additional, Safirstein, Robert L., additional, Schulman, Gerald, additional, Shah, Sudhir V., additional, Zent, Roy, additional, Wolfe, M. Michael, additional, Blanton, Wanda P., additional, Bliss, Charles M., additional, Farraye, Francis A., additional, Huang, Christopher S., additional, Jacobson, Brian C., additional, Lichtenstein, David R., additional, Lowe, Robert, additional, Mishkin, Daniel S., additional, Moore, T. Carlton, additional, Oviedo, Jaime A., additional, Pedrosa, Marcos C., additional, Schimmel, Elihu M., additional, Schroy, Paul C., additional, Singh, Satish K., additional, Tseng, Chi-Chuan, additional, Fallon, Michael B., additional, Arguedas, Miguel R., additional, Garcia-Gallont, Rudolf, additional, Kochar, Rajan, additional, McGuire, Brendan M., additional, Mönkemüller, Klaus, additional, Neumann, Helmut, additional, M. Sheikh, Aasim, additional, Varadarajulu, Shyam, additional, Berliner, Nancy, additional, Lacy, Jill, additional, S. Rinder, Christine, additional, M. Rinder, Henry, additional, G. Rose, Michal, additional, E. Seropian, Stuart, additional, Tormey, Christopher, additional, Torres, Richard, additional, Wang, Eunice S., additional, Griggs, Jennifer J., additional, Burtness, Barbara A., additional, Khorana, Alok A., additional, Lantz, Paula M., additional, Todd, Robert F., additional, Smith, Robert J., additional, Brooks, David G., additional, Gopalakrishnan, Geetha, additional, Hamdy, Osama, additional, Warren, Michelle P., additional, Ziegler, Thomas R., additional, Braunstein, Glenn D., additional, Barnett, Philip S., additional, Herman-Bonert, Vivien S., additional, Friedman, Theodore C., additional, Charney, Pamela A., additional, Carney, Patricia I., additional, Ehrenthal, Deborah B., additional, Kottenhahn, Renee K., additional, Smith, Joseph A., additional, Milam, Douglas F., additional, Starkman, Johnathan S., additional, Stewart, Andrew F., additional, Greenspan, Susan L., additional, Hodak, Steven P., additional, Horwitz, Mara J., additional, LeBeau, Shane O., additional, Roodman, G. David, additional, Moreland, Larry W., additional, Agarwal, Surabhi, additional, Ascherman, Dana P., additional, Domsic, Robyn T., additional, Elliott, Jennifer Rae, additional, Kao, Amy H., additional, Koumpouras, Fotios, additional, Kwoh, C. Kent, additional, Lienesch, Douglas W., additional, McKinnon-Maksimowicz, Kathleen, additional, Medsger, Thomas A., additional, Mohan, Niveditha, additional, Wing, Edward J., additional, Armitage, Keith B., additional, Beckwith, Curt G., additional, Bobak, David A., additional, Fairley, Jessica K., additional, Fulton, Scott A., additional, Hileman, Corrilynn O., additional, Lange, Christoph, additional, Lederman, Michael M., additional, Lemonovich, Tracy L., additional, Lisagaris, Michelle V., additional, Ray, Amy J., additional, Rodriguez, Benigno, additional, Salata, Robert A., additional, Watkins, Richard R., additional, Bradsher, Robert W., additional, Griggs, Robert C., additional, Berg, Michel J., additional, Ciafaloni, Emma, additional, Counihan, Timothy J., additional, Cheshire, William P., additional, de los Reyes, Emily C., additional, Jackson, Carlayne E., additional, Kerber, Kevin A., additional, Liu, Lynn C., additional, Ling, Geoffrey S.F., additional, Lyness, Jeffery M., additional, Lynn, Deborah Joanne, additional, Marshall, Frederick J., additional, McCarthy, Allan, additional, Murphy, Sinéad M., additional, Nath, Avindra, additional, Roach, E. Steve, additional, Rogers, Lisa R., additional, Simon, Roger P., additional, Cohen, Harvey J., additional, Heflin, Mitchell T., additional, Quill, Timothy E., additional, Holloway, Robert G., additional, Hillis, L. David, additional, and Lange, Richard A., additional

Published
2010
Full Text
View/download PDF

66. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Author

Wheeler, David C, primary, Stefansson, Bergur V, additional, Batiushin, Mikhail, additional, Bilchenko, Oleksandr, additional, Cherney, David Z I, additional, Chertow, Glenn M, additional, Douthat, Walter, additional, Dwyer, Jamie P, additional, Escudero, Elizabeth, additional, Pecoits-Filho, Roberto, additional, Furuland, Hans, additional, Górriz, José Luis, additional, Greene, Tom, additional, Haller, Hermann, additional, Hou, Fan Fan, additional, Kang, Shin-Wook, additional, Isidto, Rey, additional, Khullar, Dinesh, additional, Mark, Patrick B, additional, McMurray, John J V, additional, Kashihara, Naoki, additional, Nowicki, Michal, additional, Persson, Frederik, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Toto, Robert D, additional, Umanath, Kausik, additional, Van Bui, Pham, additional, Wittmann, István, additional, Lindberg, Magnus, additional, Sjöström, C David, additional, Langkilde, Anna Maria, additional, and Heerspink, Hiddo J L, additional

Published
2020
Full Text
View/download PDF

67. 303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial

Author

RAZ, ITAMAR, primary, WIVIOTT, STEPHEN D., additional, HEERSPINK, HIDDO L., additional, DWYER, JAMIE P., additional, CAHN, AVIVIT, additional, GOODRICH, ERICA L., additional, MURPHY, SABINA, additional, ROZENBERG, ALIZA, additional, YANUV, ILAN, additional, WILDING, JOHN, additional, LEITER, LAWRENCE A., additional, BHATT, DEEPAK L., additional, MCGUIRE, DARREN K., additional, MA, RONALD C., additional, TANKOVA, TSVETALINA, additional, FREDRIKSSON, MARTIN, additional, GAUSE-NILSSON, INGRID A., additional, LANGKILDE, ANNA MARIA, additional, SABATINE, MARC S., additional, and MOSENZON, OFRI, additional

Published
2020
Full Text
View/download PDF

73. Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT

Author

Beddhu, Srinivasan, primary, Shen, Jincheng, additional, Cheung, Alfred K., additional, Kimmel, Paul L., additional, Chertow, Glenn M., additional, Wei, Guo, additional, Boucher, Robert E., additional, Chonchol, Michel, additional, Arman, Farid, additional, Campbell, Ruth C., additional, Contreras, Gabriel, additional, Dwyer, Jamie P., additional, Freedman, Barry I., additional, Ix, Joachim H., additional, Kirchner, Kent, additional, Papademetriou, Vasilios, additional, Pisoni, Roberto, additional, Rocco, Michael V., additional, Whelton, Paul K., additional, and Greene, Tom, additional

Published
2019
Full Text
View/download PDF

74. 244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial

Author

RAZ, ITAMAR, primary, WIVIOTT, STEPHEN D., additional, YANUV, ILAN, additional, ROZENBERG, ALIZA, additional, ZELNIKER, THOMAS A., additional, CAHN, AVIVIT, additional, HEERSPINK, HIDDO L., additional, DWYER, JAMIE P., additional, GOODRICH, ERICA, additional, BHATT, DEEPAK L., additional, LEITER, LAWRENCE A., additional, MCGUIRE, DARREN K., additional, WILDING, JOHN P., additional, GAUSE-NILSSON, INGRID ANNA, additional, FREDRIKSSON, MARTIN, additional, JOHANSSON, PETER A., additional, LANGKILDE, ANNA MARIA, additional, SABATINE, MARC S., additional, and MOSENZON, OFRI, additional

Published
2019
Full Text
View/download PDF

76. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Cheung, Alfred K., primary, Chang, Tara I., additional, Cushman, William C., additional, Furth, Susan L., additional, Ix, Joachim H., additional, Pecoits-Filho, Roberto, additional, Perkovic, Vlado, additional, Sarnak, Mark J., additional, Tobe, Sheldon W., additional, Tomson, Charles R.V., additional, Cheung, Michael, additional, Wheeler, David C., additional, Winkelmayer, Wolfgang C., additional, Mann, Johannes F.E., additional, Bakris, George L., additional, Damasceno, Albertino, additional, Dwyer, Jamie P., additional, Fried, Linda F., additional, Haynes, Richard, additional, Hirawa, Nobuhito, additional, Holdaas, Hallvard, additional, Ibrahim, Hassan N., additional, Ingelfinger, Julie R., additional, Iseki, Kunitoshi, additional, Khwaja, Arif, additional, Kimmel, Paul L., additional, Kovesdy, Csaba P., additional, Ku, Elaine, additional, Lerma, Edgar V., additional, Luft, Friedrich C., additional, Lv, Jicheng, additional, McFadden, Christopher B., additional, Muntner, Paul, additional, Myers, Martin G., additional, Navaneethan, Sankar D., additional, Parati, Gianfranco, additional, Peixoto, Aldo J., additional, Prasad, Ramesh, additional, Rahman, Mahboob, additional, Rocco, Michael V., additional, Rodrigues, Cibele Isaac Saad, additional, Roger, Simon D., additional, Stergiou, George S., additional, Tomlinson, Laurie A., additional, Tonelli, Marcello, additional, Toto, Robert D., additional, Tsukamoto, Yusuke, additional, Walker, Robert, additional, Wang, Angela Yee-Moon, additional, Wang, Jiguang, additional, Warady, Bradley A., additional, Whelton, Paul K., additional, and Williamson, Jeff D., additional

Published
2019
Full Text
View/download PDF

77. Once-Daily Plazomicin for Complicated Urinary Tract Infections

Author

Wagenlehner, Florian M.E., primary, Cloutier, Daniel J., additional, Komirenko, Allison S., additional, Cebrik, Deborah S., additional, Krause, Kevin M., additional, Keepers, Tiffany R., additional, Connolly, Lynn E., additional, Miller, Loren G., additional, Friedland, Ian, additional, and Dwyer, Jamie P., additional

Published
2019
Full Text
View/download PDF

79. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Author

Bohula, Erin A, primary, Scirica, Benjamin M, additional, Inzucchi, Silvio E, additional, McGuire, Darren K, additional, Keech, Anthony C, additional, Smith, Steven R, additional, Kanevsky, Estella, additional, Murphy, Sabina A, additional, Leiter, Lawrence A, additional, Dwyer, Jamie P, additional, Corbalan, Ramon, additional, Hamm, Christian, additional, Kaplan, Lee, additional, Nicolau, Jose Carlos, additional, Ophuis, Ton Oude, additional, Ray, Kausik K, additional, Ruda, Mikhail, additional, Spinar, Jindrich, additional, Patel, Tushar, additional, Miao, Wenfeng, additional, Perdomo, Carlos, additional, Francis, Bruce, additional, Dhadda, Shobha, additional, Bonaca, Marc P, additional, Ruff, Christian T, additional, Sabatine, Marc S, additional, Wiviott, Stephen D, additional, Inzucchi, Silvio, additional, Keech, Anthony, additional, Satlin, Andrew, additional, Brown, Conville, additional, Budaj, Andrzej, additional, Dwyer, Jamie, additional, Garcia-Castillo, Armando, additional, Gupta, Milan, additional, Oude Ophuis, Ton, additional, Ray, Kauski, additional, Weissman, Neil, additional, White, Harvey D, additional, Amerena, J, additional, Arstall, M, additional, Colquhoun, D, additional, Jayasinghe, R, additional, Lee, A, additional, Lehman, R, additional, Moses, R, additional, Proietto, J, additional, Purnell, P, additional, Waites, J, additional, Blombery, P, additional, Cross, D, additional, Worthley, M, additional, d'Emden, M, additional, Selvanayagam, J, additional, Oqueli, RE, additional, Whelan, A, additional, Garrahy, P, additional, de Looze, F, additional, Ninio, D, additional, Horowitz, J, additional, William, M, additional, Suranyi, M, additional, Wittert, G, additional, Le May, M, additional, Pandey, AS, additional, Vizel, S, additional, Labonte, R, additional, Beaudry, Y, additional, Fortin, C, additional, Bell, A, additional, Kouz, S, additional, St-Amour, É, additional, Bata, I, additional, St Maurice, F, additional, Chehayeb, R, additional, Constance, C, additional, Wong, G, additional, Hess, A, additional, Liutkus, J, additional, Poirier, P, additional, Teitelbaum, I, additional, Berlingieri, J, additional, Cha, J, additional, Hartleib, M, additional, Heffernan, M, additional, Twum-Barima, D, additional, Pandith, V, additional, Aronson, R, additional, Goldenberg, R, additional, Ajala, B, additional, Jain, A, additional, Ross, S, additional, Bajaj, H, additional, Khandwala, H, additional, Yared, Z, additional, Gupta, N, additional, Bédard, J, additional, Wharton, S, additional, Blouin, F, additional, Savard, D, additional, Shukla, D, additional, Cobos, J, additional, Godoy, G, additional, Perez, L, additional, Pincetti, C, additional, Saavedra Guajardo, V, additional, Varleta, P, additional, Conejeros, C, additional, Lanas, F, additional, Bayram Llamas, E, additional, Cardona Muñoz, E, additional, Garcia, R, additional, Garza Ruiz, J, additional, Llamas Esperon, G, additional, Lopez Rosas, E, additional, Melendez Mier, G, additional, Ramos, G, additional, Hart, H, additional, Scott, D, additional, Ternouth, I, additional, Benatar, J, additional, Elliott, J, additional, Cutfield, R, additional, Manning, P, additional, Williams, M, additional, Ferrier, K, additional, Scott, R, additional, Wilson, S, additional, Leikis, R, additional, Nirmalaraj, BK, additional, Krzyżagórska, E, additional, Miękus, P, additional, Bronisz, M, additional, Mirek-Bryniarska, E, additional, Łanda, K, additional, Stasiewski, A, additional, Żechowicz, T, additional, Zytkiewicz-Jaruga, D, additional, Korecki, J, additional, Ogórek, M, additional, Pawłowicz, L, additional, Piepiorka, M, additional, Skierkowska, J, additional, Stankiewicz, A, additional, Szyprowska, E, additional, Witek, R, additional, Bochenek, A, additional, Kończakowski, P, additional, Wojnowski, Ł, additional, Wujkowski, M, additional, Cymerman, K, additional, Korzeniak, R, additional, Mąder, P, additional, Mikłaszewicz, B, additional, Stachlewski, P, additional, Goch, A, additional, Pomiećko, W, additional, Skórski, M, additional, Romanowski, L, additional, Jusiak, K, additional, Laskowska-Derlaga, E, additional, Bijata-Bronisz, R, additional, Kaźmierczak, J, additional, Goldberg, R, additional, Henderson, D, additional, Korban, E, additional, Rohr, K, additional, Claxton, E, additional, Weiss, R, additional, Angiolillo, D, additional, Boccalandro, F, additional, Chu, K, additional, Thorn, E, additional, Randhawa, P, additional, Singh, N, additional, Bittar, G, additional, Guarnieri, T, additional, Saeed, S, additional, Sharma, S, additional, Shepard, M, additional, French, W, additional, Desai, P, additional, Bernstein, R, additional, Rogers, W, additional, Singal, R, additional, Schneider, R, additional, Shanes, J, additional, Ong, S, additional, Condit, J, additional, Donahoe, S, additional, Brill, D, additional, Einhorn, D, additional, Ebrahimi, R, additional, Labroo, A, additional, Graf, R, additional, Scott, J, additional, Hoekstra, J, additional, Jetty, P, additional, Luckasen, G, additional, O'Donnell, P, additional, Gonte, W, additional, Pomposini, D, additional, Quadrel, M, additional, Koren, M, additional, Schlager, D, additional, Schramm, E, additional, Singal, D, additional, Lupovitch, S, additional, Soni, A, additional, Seigel, P, additional, Roberts, J, additional, Soufer, J, additional, Reza, S, additional, Quinlan, E, additional, Moretto, T, additional, First, B, additional, Khan, M, additional, Chilka, S, additional, Colfer, H, additional, Teklinski, A, additional, Wallace-Wilding, K, additional, Ellison, H, additional, Muse, D, additional, Aronoff, S, additional, Higgins, A, additional, Patel, S, additional, Elinoff, V, additional, Karim, A, additional, Awasty, V, additional, Chuang, R, additional, Roseman, H, additional, Dugano-Daphnis, P, additional, Albert, M, additional, Sheikh, K, additional, Bays, H, additional, Kaster, S, additional, Goldstein, M, additional, Rubino, D, additional, Calatayud, G, additional, Snyder, H, additional, Williams, T, additional, Hershon, K, additional, Hagan, M, additional, Isserman, S, additional, Kahn, B, additional, Anderson, J, additional, Gimness, MP, additional, Raisinghani, A, additional, Christina, M, additional, Raikhel, M, additional, Gillespie, E, additional, Portnay, E, additional, Heiman, M, additional, Qureshi, M, additional, Lee, J, additional, Blonder, R, additional, Cucher, F, additional, Miller, G, additional, Kotlaba, D, additional, Cornett, G, additional, Beavins, J, additional, Augenbraun, C, additional, Reinhardt, S, additional, Bartkowiak, A, additional, Salacata, A, additional, Blevins, T, additional, Benjamin, S, additional, Diener, J, additional, George, W, additional, Barker, B, additional, Richwine, R, additional, Baldari, D, additional, Alfieri, A, additional, Barreto, A, additional, Zhang, L, additional, Shah, R, additional, Hendrix, E, additional, Subramaniyam, V, additional, Hurley, S, additional, Lillestol, M, additional, O'Donoghue, M, additional, Shayani, S, additional, Ryan, E, additional, Call, R, additional, Zemel, L, additional, Chang, A, additional, Kivitz, A, additional, Freyne, B, additional, Bland, V, additional, Shore, K, additional, Mostel, E, additional, Uzoaga, E, additional, Andrawis, N, additional, Gabra, N, additional, Ghitis, A, additional, Sabatino, K, additional, Browder, D, additional, Varma, S, additional, Smith, S, additional, Fink, R, additional, Aycock, GR, additional, Doty, WD, additional, Alfonso, T, additional, Eshaghian, S, additional, Karlsberg, R, additional, Zarich, S, additional, Landau, C, additional, McKenzie, M, additional, Krause, R, additional, Davis, W, additional, Haddad, T, additional, Voyce, S, additional, Alford, C, additional, LeDoux, J, additional, O'Dea, D, additional, Park, J, additional, Aroda, V, additional, Getaneh, A, additional, Graham, B, additional, Bhagwat, R, additional, Korn, D, additional, Ruoff, G, additional, Wiseman, A, additional, Lieber, I, additional, Fialkow, J, additional, Gonzalez-Campoy, JM, additional, Bayron, C, additional, Bertolet, B, additional, Lash, J, additional, Gerrish, C, additional, Robertson, D, additional, Rosenfeld, J, additional, Seidner, M, additional, Agaiby, J, additional, Silverfield, J, additional, Sugimoto, D, additional, Lubin, B, additional, Alhaddad, M, additional, Lui, H, additional, Lakin, G, additional, Chokshi, S, additional, Donovan, D, additional, Felten, W, additional, Minton, S, additional, Kimmelstiel, C, additional, Kuvin, J, additional, Still, C, additional, Byars, W, additional, Talano, J, additional, Desai, V, additional, Bradley, AJ, additional, Baker, S, additional, Chane, M, additional, Mercado, A, additional, Baron, S, additional, Harris, B, additional, Mayer, N, additional, Concha, M, additional, Carr, K, additional, Chaykin, L, additional, Willis, J, additional, Clay, A, additional, Fenstad, E, additional, Furda, J, additional, Peterson, P, additional, Chang, M, additional, Aronne, L, additional, Jones, D, additional, Prashad, R, additional, Benson, M, additional, Stegemoller, R, additional, Longshaw, K, additional, Saleh, J, additional, Jennings, W, additional, Detweiler, R, additional, Viswanath, D, additional, Patel, R, additional, Lederman, S, additional, Weinstein, D, additional, Korabathina, R, additional, Singh, V, additional, Rosen, J, additional, Estevez, R, additional, Levin, P, additional, McNeill, R, additional, Kalen, V, additional, Reed, J, additional, Ashley, R, additional, Herman, L, additional, Tsai, Y, additional, Kayne, D, additional, White, A, additional, Hussain, I, additional, Tami, L, additional, Cohen, K, additional, Robinson, J, additional, Fuchs-Ertman, D, additional, Platt, G, additional, Belardo, L, additional, Reddy, R, additional, Rosendorff, C, additional, Saba, F, additional, Powell, S, additional, Anderson, K, additional, Abidi, M, additional, Rezkalla, S, additional, Paraschos, A, additional, Wilson, J, additional, Moursi, M, additional, Shah, A, additional, Nadar, V, additional, Stonesifer, L, additional, Bialow, M, additional, Cannon, K, additional, Ellison, W, additional, Stedman, M, additional, Brown, J, additional, Harper, W, additional, Lucas, KJ, additional, DiGiovanna, M, additional, Rodbard, H, additional, Biscoveanu, M, additional, Davis, C, additional, Hall, J, additional, Littlefield, R, additional, Gorman, T, additional, Kereiakes, D, additional, Chang, FM, additional, Tatu, H, additional, Cheung, D, additional, Kaine, J, additional, Knutson, T, additional, Logemann, T, additional, Pueblitz, G, additional, Bianco, J, additional, Henson, B, additional, Neustel, M, additional, Gelernt, M, additional, Nelson, W, additional, Moriarty, K, additional, Lefebvre, G, additional, Maw, K, additional, Rink, L, additional, Behn, P, additional, Studdard, H, additional, Argoud, G, additional, O'Connor, T, additional, Krichmar, P, additional, Raad, G, additional, Pereles-Ortiz, J, additional, Sorli, C, additional, Cohen, A, additional, Pettis, K, additional, Cavanaugh, B, additional, Phillips, C, additional, Wahlen, J, additional, Radin, D, additional, Rider, J, additional, Kosinski, E, additional, Leimbach, W, additional, Odhav, A, additional, Hakas, J, additional, Tan, A, additional, Howell, M, additional, Wombolt, D, additional, Fishman, N, additional, Shah, P, additional, Wylie, P, additional, Arauz-Pacheco, C, additional, Cavale, A, additional, George, A, additional, Kroll, R, additional, Krantzler, J, additional, Tahirkheli, N, additional, Jabro, M, additional, Newell, M, additional, Mullen, P, additional, Gencheff, N, additional, Meli, J, additional, Vora, K, additional, Kotek, L, additional, Pyzdrowski, K, additional, Paez, H, additional, Moran, J, additional, Tannenbaum, A, additional, Deck, K, additional, Busch, R, additional, Levinson, L, additional, Azizad, M, additional, Whitaker, J, additional, Fox, B, additional, Huffman, C, additional, Ashraf, M, additional, Diogo, J, additional, Kushner, R, additional, Tallet, J, additional, Channamsetty, V, additional, Suh, D, additional, Atieh, M, additional, Navas, J, additional, Young, V, additional, Shaw, S, additional, Dor, I, additional, Duffy, B, additional, Rubin, P, additional, Lewis, D, additional, Kaye, W, additional, Benton, R, additional, Burbano, J, additional, Hotchkiss, D, additional, Magno, A, additional, Alberton, A, additional, Collins, J, additional, Alvarado, O, additional, Stich, M, additional, Mahal, S, additional, Liu, J, additional, Hong, M, additional, Dy, J, additional, Block, B, additional, Lamantia, J, additional, Pritchard, J, additional, Davis, M, additional, Srivastava, S, additional, Bilazarian, S, additional, Rosario, R, additional, McCartney, M, additional, Blumberg, V, additional, Rajan, R, additional, Martin, E, additional, Wright, S, additional, Brinson, C, additional, Johnston, J, additional, Graves, M, additional, Dominguez, M, additional, McKenzie, W, additional, Abadier, R, additional, Tran, C, additional, Castello, R, additional, Morawski, E, additional, White, J, additional, Morris, F, additional, Perez, A, additional, Trueba, P, additional, Sanchez, M, additional, Andersen, J, additional, Kastelic, R, additional, Khan, J, additional, Rodriguez, H, additional, Izquierdo, W, additional, Matias, A, additional, Essandoh, L, additional, and Ince, C, additional

Published
2018
Full Text
View/download PDF

80. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Author

Adler, Amanda, Agodoa, Larry, Algra, Ale, Asselbergs, Folkert W, Beckett, Nigel S, Berge, Eivind, Black, Henry, Brouwers, Frank P J, Brown, Morris, Bulpitt, Christopher J, Byington, Robert P, Chalmers, John, Cushman, William C, Cutler, Jeffrey, Davis, Barry R, Devereaux, Richard B, Dwyer, Jamie, Estacio, Ray, Fagard, Robert, Fox, Kim, Fukui, Tsuguya, Gupta, Ajay K, Holman, Rury R, Imai, Yutaka, Ishii, Masao, Julius, Stevo, Kanno, Yoshihiko, Kjeldsen, Sverre E, Kostis, John, Kuramoto, Kizuku, Lanke, Jan, Lewis, Edmund, Lewis, Julia B, Lievre, Michel, Lindholm, Lars H, Lueders, Stephan, MacMahon, Stephen, Mancia, Giuseppe, Matsuzaki, Masunori, Mehlum, Maria H, Nissen, Steven, Ogawa, Hiroshi, Ogihara, Toshio, Ohkubo, Takayoshi, Palmer, Christopher R, Patel, Anushka, Pepine, Carl J, Pfeffer, Marc Allan, Pitt, Bertram, Poulter, Neil R, Rakugi, Hiromi, Reboldi, Giuseppe, Reid, Christopher, Remuzzi, Giuseppe, Ruggenenti, Piero, Saruta, Takao, Schrader, Joachim, Schrier, Robert, Sever, Peter, Sleight, Peter, Staessen, Jan A, Suzuki, Hiromichi, Thijs, Lutgarde, Ueshima, Kenji, Umemoto, Seiji, van Gilst, Wiek H, Verdecchia, Paolo, Wachtell, Kristian, Whelton, Paul, Wing, Lindon, Woodward, Mark, Yui, Yoshiki, Yusuf, Salim, Zanchetti, Alberto, Zhang, Zhen-Yu, Anderson, Craig, Baigent, Colin, Brenner, Barry Morton, Collins, Rory, de Zeeuw, Dick, Lubsen, Jacobus, Malacco, Ettore, Neal, Bruce, Perkovic, Vlado, Rodgers, Anthony, Rothwell, Peter, Salimi-Khorshidi, Gholamreza, Sundström, Johan, Turnbull, Fiona, Viberti, Giancarlo, and Wang, Jiguang

Abstract

The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure.

Published
2021
Full Text
View/download PDF

82. Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants

Author

Supiano, Mark A., primary, Lovato, Laura, additional, Ambrosius, Walter T., additional, Bates, Jeffrey, additional, Beddhu, Srinivasan, additional, Drawz, Paul, additional, Dwyer, Jamie P., additional, Hamburg, Naomi M., additional, Kitzman, Dalane, additional, Lash, James, additional, Lustigova, Eva, additional, Miracle, Cynthia M., additional, Oparil, Suzanne, additional, Raj, Dominic S., additional, Weiner, Daniel E., additional, Taylor, Addison, additional, Vita, Joseph A., additional, Yunis, Reem, additional, Chertow, Glenn M., additional, and Chonchol, Michel, additional

Published
2018
Full Text
View/download PDF

83. Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)

Author

Shapiro, Brian P., primary, Ambrosius, Walter T., additional, Blackshear, Joseph L., additional, Cushman, William C., additional, Whelton, Paul K., additional, Oparil, Suzanne, additional, Beddhu, Srinivasan, additional, Dwyer, Jamie P., additional, Gren, Lisa H., additional, Kostis, William J., additional, Lioudis, Michael, additional, Pisoni, Roberto, additional, Rosendorff, Clive, additional, and Haley, William E., additional

Published
2018
Full Text
View/download PDF

85. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)

Author

Rocco, Michael V., primary, Sink, Kaycee M., additional, Lovato, Laura C., additional, Wolfgram, Dawn F., additional, Wiegmann, Thomas B., additional, Wall, Barry M., additional, Umanath, Kausik, additional, Rahbari-Oskoui, Frederic, additional, Porter, Anna C., additional, Pisoni, Roberto, additional, Lewis, Cora E., additional, Lewis, Julia B., additional, Lash, James P., additional, Katz, Lois A., additional, Hawfield, Amret T., additional, Haley, William E., additional, Freedman, Barry I., additional, Dwyer, Jamie P., additional, Drawz, Paul E., additional, Dobre, Mirela, additional, Cheung, Alfred K., additional, Campbell, Ruth C., additional, Bhatt, Udayan, additional, Beddhu, Srinivasan, additional, Kimmel, Paul L., additional, Reboussin, David M., additional, and Chertow, Glenn M., additional

Published
2018
Full Text
View/download PDF

87. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.

Author

CAMELLIA-TIMI 61 Steering Committee and Investigators, Scirica, Benjamin M., Bohula, Erin A., Qamar, Arman, Murphy, Sabina A., Im, Kyungah, Bonaca, Marc P., Ruff, Christian T., Sabatine, Marc S., Wiviott, Stephen D., Sabatine, Marc, Dwyer, Jamie P., Inzucchi, Silvio E., McGuire, Darren K., Keech, Anthony C., Smith, Steven R., Leiter, Lawrence A., Gupta, Milan, Patel, Tushar, and Miao, Wenfeng

Published
2019
Full Text
View/download PDF

89. Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical Trials.

Author

Harris, Paul A., Dunsmore, Sarah E., Atkinson, Jane C., Benjamin Jr, Daniel Kelly, Bernard, Gordon R., Dean, J. Michael, Dwyer, Jamie P., Ford, Daniel F., Selker, Harry P., Waddy, Salina P., Wiley, Kenneth L., Wilkins, Consuelo H., Cook, Sarah K., Burr, Jeri S., Edwards, Terri L., Huvane, Jacqueline, Kennedy, Nan, Lane, Karen, Majkowski, Ryan, and Nelson, Sarah

Published
2023
Full Text
View/download PDF

90. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases

Author

Irizarry-Alvarado, Joan M., Dwyer, Jamie P., Brumble, Lisa M., Alvarez, Salvador, and Mendez, Julio C.

Subjects
Diabetes insipidus -- Risk factors, Diabetes insipidus -- Diagnosis, Diabetes insipidus -- Research, Didanosine -- Complications and side effects, Kidney diseases -- Risk factors, Kidney diseases -- Diagnosis, Kidney diseases -- Research, Tenofovir -- Complications and side effects, Health
Abstract

We report 3 cases of patients with HIV/AIDS in whom Fanconi syndrome and nephrogenic diabetes insipidus developed secondary to use of an antiretroviral regimen containing tenofovir disoproxil fumarate and didanosine. These patients presented with a history of polydipsia, polyuria, weight loss, anorexia, and wasting. Interestingly, 1 patient was not taking protease inhibitors. This response is a well-documented yet uncommon complication of tenofovir use in the HIV population. We recommend continued monitoring for renal toxicity when using the NRTI combination of tenofovir and didanosine. Key words: HIV/AIDS * Fanconi syndrome * Kidney disease * Diabetes * Antiretroviral therapy * NRTIs * Tenofovir * Didanosine, The availability of highly active antiretroviral therapy has improved the survival and quality of life of patients infected with HIV. Clinicians are now focusing on the management of metabolic complications [...]

Published
2009

93. Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial

Author

Chang, Tara I., primary, Evans, Gregory, additional, Cheung, Alfred K., additional, Cushman, William C., additional, Diamond, Matthew J., additional, Dwyer, Jamie P., additional, Huan, Yonghong, additional, Kitzman, Dalane, additional, Kostis, John B., additional, Oparil, Suzanne, additional, Rastogi, Anjay, additional, Roumie, Christianne L., additional, Sahay, Rukmani, additional, Stafford, Randall S., additional, Taylor, Addison A., additional, Wright, Jackson T., additional, and Chertow, Glenn M., additional

Published
2016
Full Text
View/download PDF

94. Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial).

Author

for the SPRINT Research Group, Shapiro, Brian P., Blackshear, Joseph L., Lioudis, Michael, Pisoni, Roberto, Rosendorff, Clive, Haley, William E., Ambrosius, Walter T., Cushman, William C., Whelton, Paul K., Oparil, Suzanne, Beddhu, Srinivasan, Dwyer, Jamie P., Gren, Lisa H., Kostis, William J., and SPRINT Research Group*

Abstract

Intensive systolic blood pressure (SBP) control improved outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Our objective was to expand on reported findings by analysis of baseline characteristics, primary outcomes, adverse events, follow-up blood pressure, and medication use differences by baseline SBP (tertile 1 [T1], <132; tertile 2 [T2], 132-145; and tertile 3 [T3], >145 mm Hg). Participants with higher baseline SBP tertile were more often women and older, had higher cardiovascular risk, and lower utilization of antihypertensive medications, statins, and aspirin. Achieved SBP in both treatment arms was slightly higher in T2 and T3 compared with T1 and fewer in the T3 groups achieved SBP targets compared with T1 and T2 groups. The primary composite outcome with intensive versus standard SBP treatment was reduced by 30% in T1, 23% in T2, and 17% in T3 with no evidence of an interaction (P=0.77). Event rates were lower in the intensive arm, and there was no evidence that this benefit differed by SBP tertile. There was no difference in the hazard for serious adverse events in any of the 3 tertiles. Medication utilization differed across the SBP tertiles at baseline with a lesser percentage of diuretics and angiotensin-converting enzyme inhibitors/angiotensin receptor blocker drugs in the higher tertiles-a finding that reversed during the trial. The beneficial effects of intensive SBP lowering were not modified by the level of baseline SBP. Within the parameters of this population, these findings add support for clinicians to treat blood pressure to goal irrespective of baseline SBP. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

95. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Author

Heerspink, Hiddo J L, Greene, Tom, Tighiouart, Hocine, Gansevoort, Ron T, Coresh, Josef, Simon, Andrew L, Chan, Tak Mao, Hou, Fan Fan, Lewis, Julia B, Locatelli, Francesco, Praga, Manuel, Schena, Francesco Paolo, Levey, Andrew S, Inker, Lesley A, Sevillano, Angel, Kamper, Anne-Lise, van Zuilen, Arjan D., Brenner, Barry M., Maes, Bart, Ihle, Benno U., Barret, Brendan, Leung, CB, Szeto, CC, Fitzner, Christina, Wanner, Christoph, Pozzi, Claudio, Montagnino, Claudio Ponticelli, Xie, Di, de Zeeuw, Dick, Lewis, Edmund, Verde, Eduardo, Gutierrez, Eduardo, Imai, Enyu, Hou, Fan Fan, Caravaca, Fernando, Fervenza, Fernando C., Locatelli, Francesco, Schena, Francesco Paolo, Kobayashi, Fumiaki, Moroni, Gabriella, Becker, Gavin J., Beck, Gerald J., Appel, Gerald B., Frisch, Gershon, van Essen, GG, Maschio, Giuseppe, Remuzzi, Giuseppe, Montogrino, Giuseppe, Parving, Hans-Henrik, Heerspink, Hiddo J.L., Makino, Hirofumi, Jehan, Imitiaz, Wetzels, Jack F.M., Donadio, James, Dwyer, Jamie, van den Brand, Jan, Kusek, John, Lachin, John M., Luño, Jose, Lewis, Julia B., Floege, Jürgen, Abebe, Kaleab Z., Chow, KM, Hunsicker, Lawrence G., del Vecchio, Lucia, Carlo, Manno, Praga, Manuel, Goicoechea, Marian, von Eynatten, Maximilian, Poulter, Neil, Chaturvedi, Nish, Passerini, Patrizia, de Jong, Paul E., Blankestijn, Peter J., Li, Philip, Ruggenenti, Piero, Zucchelli, Pietro, Kincaid-Smith, Priscilla S., Hilgers, Ralf-Dieter, Estacio, Raymond O., Rohde, Richard D., Katafuchi, Ritsuko, Toto, Robert D., Schrier, Robert W., Rodby, Roger A., Perrone, Ronald D., Ito, Sadayoshi, Klahr, Saulo, Andrulli, Simeone, Strandgaard, Svend, Chan, Tak Mao, Hannedouche, Thierry P., Rauen, Thomas, Greene, Tom, Verdalles, Ursula, Perkovic, Vlado, and Keane, William

Abstract

Change in albuminuria has strong biological plausibility as a surrogate endpoint for progression of chronic kidney disease, but empirical evidence to support its validity is lacking. We aimed to determine the association between treatment effects on early changes in albuminuria and treatment effects on clinical endpoints and surrograte endpoints, to inform the use of albuminuria as a surrogate endpoint in future randomised controlled trials.

Published
2019
Full Text
View/download PDF

96. Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD

Author

Umanath, Kausik, primary, Jalal, Diana I., additional, Greco, Barbara A., additional, Umeukeje, Ebele M., additional, Reisin, Efrain, additional, Manley, John, additional, Zeig, Steven, additional, Negoi, Dana G., additional, Hiremath, Anand N., additional, Blumenthal, Samuel S., additional, Sika, Mohammed, additional, Niecestro, Robert, additional, Koury, Mark J., additional, Ma, Khe-Ni, additional, Greene, Tom, additional, Lewis, Julia B., additional, and Dwyer, Jamie P., additional

Published
2015
Full Text
View/download PDF

97. SP657GASTROINTESTINAL SAFETY AND TOLERABILITY OF FERRIC CITRATE IN PATIENTS WITH ESRD ON DIALYSIS: A POOLED ANALYSIS

Author

Chernin, Gil, primary, Chang, Ingrid J, additional, Bhatt, Udayan, additional, Ortiz, Andrea, additional, Barry, Sean, additional, Sika, Mohammed, additional, Lewis, Julia B, additional, Umanath, Kausik, additional, Koury, Mark, additional, Yagil, Yoram, additional, Niecestro, Robert, additional, and Dwyer, Jamie P, additional

Published
2015
Full Text
View/download PDF

98. Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis

Author

Lewis, Julia B., primary, Sika, Mohammed, additional, Koury, Mark J., additional, Chuang, Peale, additional, Schulman, Gerald, additional, Smith, Mark T., additional, Whittier, Frederick C., additional, Linfert, Douglas R., additional, Galphin, Claude M., additional, Athreya, Balaji P., additional, Nossuli, A. Kaldun Kaldun, additional, Chang, Ingrid J., additional, Blumenthal, Samuel S., additional, Manley, John, additional, Zeig, Steven, additional, Kant, Kotagal S., additional, Olivero, Juan Jose, additional, Greene, Tom, additional, and Dwyer, Jamie P., additional

Published
2015
Full Text
View/download PDF

100. Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis.

Author

Jalal, Diana, McFadden, Molly, Dwyer, Jamie P., Umanath, Kausik, Aguilar, Erwin, Yagil, Yoram, Greco, Barbara, Sika, Mohammed, Lewis, Julia B., Greene, Tom, and Goral, Simin

Subjects
IRON compounds, HYPERPHOSPHATEMIA, KIDNEY disease treatments, THERAPEUTICS
Abstract

Introduction: Oral phosphate binders are the main stay of treatment of hyperphosphatemia. Adherence rates to ferric citrate, a recently approved phosphate binder, are unknown. Methods: We conducted a post-hoc analysis to evaluate whether adherence rates were different for ferric citrate vs. active control in 412 subjects with end stage kidney disease (ESKD) who were randomized to ferric citrate vs. active control (sevelamer carbonate and/or calcium acetate). Adherence was defined as percent of actual number of pills taken to total number of pills prescribed. Findings: There were no significant differences in baseline characteristics including gender, race/ethnicity, and age between the ferric citrate and active control groups. Baseline phosphorus, calcium, and parathyroid hormone levels were similar. Mean (SD) adherence was 81.4% (17.4) and 81.7% (15.9) in the ferric citrate and active control groups, respectively (P = 0.88). Adherence remained similar between both groups after adjusting for gender, race/ethnicity, age, cardiovascular disease (CVD), and diabetic nephropathy (mean [95% CI]: 81.4% [78.2, 84.6] and 81.5% [77.7, 85.2] for ferric citrate and active control, respectively). Gender, race/ethnicity, age, and diagnosis of diabetic nephropathy did not influence adherence to the prescribed phosphate binder. Subjects with CVD had lower adherence rates to phosphate binder; this was significant only in the active control group. Discussion: Adherence rates to the phosphate binder, ferric citrate, were similar to adherence rates to active control. Similar adherence rates to ferric citrate are notable since tolerance to active control was an entry criteria and the study was open label. Gender, race/ethnicity, nor age influenced adherence. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results